risks of glp 1 medications GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing kidney failure. Adverse events are mostly gastrointestinal Stopping GLP-1 drugs can quickly

The absence of OCTN3 in humans, together with the OCT1 functional difference between humans and rodents, is a critical issue that limits the use of mice as a model

Discovery of GLP-1 In the mid to late 20th century, intestinal extracts were found to have blood glucose lowering effect

Researchers compared about 132,000 patients who took GLP-1 drugs with more than 201,000 who used older diabetes drugs called sulfonylureas

We used the same REML Mixed Model separately for each outcome (total GSH, free GSH, GSSG, or the ratio of free GSH to GSSG)

Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells